开放获取期刊获得更多读者和引用
700 种期刊 和 15,000,000 名读者 每份期刊 获得 25,000 多名读者
Chandasana Gamal
A persistent fungal infection that is common all over the world is fungus keratitis. Even the patient's life and health may be impacted. Natamycin is currently the first-line treatment for fungal keratitis, despite the fact that it has poor water solubility and low drug absorption in clinical settings. To test the viability of using chitosan and NAT together for eye therapy, simple natamycin-chitosan nanoparticles were used. The antifungal property of chitosan NPs was demonstrated by the results to have improved the antifungal effect of NAT. Due to their strong bacteriostasis, NAT-NPs are therefore anticipated to become promising options for the treatment of fungal keratitis.